• Siemens Healthineers secured CE mark for 24 capillary blood testing claims on its Atellica CH, IM, and CI analyzers.
• Move expands on-label capillary testing for core labs, targeting higher throughput using existing Atellica infrastructure.
• In the US, capillary claims currently cover four assays; additional FDA submissions are under regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Siemens Healthineers AG published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.